Rate My Professor Ben Forbes

Professor Ben Forbes is Professor of Pharmaceutics in Pharmaceutical Sciences at King’s College London, serving as Joint Head of the School of Cancer & Pharmaceutical Sciences and Head of the Institute of Pharmaceutical Science. He holds a BPharm degree from King’s College London, awarded in 1987, and a PhD in Drug Delivery from the University of Strathclyde in 1996. Prior to commencing his doctoral studies, Forbes worked in hospital pharmacy settings in London and Sydney, and held a position at Inveresk Clinical Research in Edinburgh. He was appointed to the academic staff of King’s College London in 1997, achieved the rank of Professor in 2016, and continues as a registered pharmacist in the UK.

The core of Professor Forbes’ research specializations includes the formulation of inhaled medicines, development and application of techniques to study respiratory drug transport and metabolism, and inhalation toxicology. As head of the Medicines Development Research Group, his team advances novel materials, formulations, drug delivery devices, manufacturing processes, analytical methods, and digital technologies essential for medicine development. He also participates in the Antimicrobial Research Theme. Forbes originated the term ‘Inhalation Biopharmaceutics’ to define the discipline addressing factors that influence respiratory and systemic exposure to inhaled drugs. His key publications encompass 'Pulmonary delivery of LNP-mRNAs aerosolised by vibrating mesh nebuliser' (2025), 'Particulate bioaerogels for respiratory drug delivery' (2024), 'A Design of Experiments Approach to Identify Critical Processing Parameters' (2025), 'The Use of Natural Polysaccharides in Spray-dried Microparticles' (2024), and 'Improving drug delivery for Alzheimer’s disease through nose-to-brain transport' (2021). He chairs the Scientific Advisory Committee of the Aerosol Society’s annual Drug Delivery to the Lung conference, contributes to pharmacy education, and supports the development of medicines for clinical evaluation, including recent advances in chemotherapy restoration for resistant cancers and optimised experimental designs.